Cargando…
Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
Dupilumab is the first biological agent approved for treatment of moderate‐to‐severe atopic dermatitis (AD). Evidence of Dupilumab effectiveness on psychological outcomes beyond 16 weeks of treatment from real‐life settings is lacking. To evaluate the effectiveness of Dupilumab treatment up to 32 we...
Autores principales: | Miniotti, Marco, Lazzarin, Giulia, Ortoncelli, Michela, Mastorino, Luca, Ribero, Simone, Leombruni, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286472/ https://www.ncbi.nlm.nih.gov/pubmed/35218275 http://dx.doi.org/10.1111/dth.15407 |
Ejemplares similares
-
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023) -
Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report
por: Gelato, Federica, et al.
Publicado: (2022) -
Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
por: Mastorino, Luca, et al.
Publicado: (2022) -
Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study
por: Mastorino, Luca, et al.
Publicado: (2021) -
Dupilumab for atopic dermatitis
Publicado: (2019)